SERMONIX NEW LOGO JPEG (2).jpg
Sermonix and Henlius Dose First Chinese Patient in Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
26. Dezember 2024 15:38 ET | Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...